Ohio State Study Follows VETS Grant Recipients for Nine Months After Psychedelic Treatment

A study followed 113 U.S. veterans treated with ibogaine and 5-MeO-DMT in Mexico; 90 completed the nine-month assessment, with researchers reporting large, statistically significant reductions in self-reported PTSD, depression, anxiety and suicidal ideation. The findings do not establish causation or safety: the study had no comparison group, relied on surveys, and nearly half of participants reported additional psychedelic use. Researchers called for randomized controlled trials, direct medical monitoring and longer-term follow-up.

Analysis

Investment read-through is limited: this is a small, uncontrolled, self-reported cohort, not evidence of efficacy or safety sufficient to support a commercial revenue case. The combined-treatment design, selected participants, follow-up attrition, and substantial additional psychedelic use by follow-up weaken attribution. The study’s own call for cardiovascular monitoring is particularly important for ibogaine: any future path likely requires costly, standardized clinical protocols, and safety findings could dominate the efficacy narrative.

Over the next 1–3 months, the main catalyst is whether the publication prompts funded controlled trials or merely advocacy and media attention. Over 6–18 months, reproducible results and acceptable monitored safety—not this observational signal—would be needed to change the sector’s commercial outlook. For psychedelic developers such as Compass Pathways and atai Life Sciences, this is not a direct read-through: different compounds and trial programs mean no basis to revise their company-specific forecasts from this study. A second-order risk is that attention to treatment abroad raises scrutiny of access pathways before domestic clinical evidence or regulatory standards are settled.

Contrarian angle: positive symptom scores may be over-weighted by advocates and investors, while the strongest actionable information is the research design’s explicit uncertainty and the likely burden of safety monitoring. No material listed-company trade is justified on this release alone.

Key Decisions for Investors

• No event-driven position based on the publication; treat it as low-impact sector sentiment, not a commercial validation catalyst.
• Watch for randomized, controlled trials with standardized protocols, objective cardiovascular monitoring, and independently reported retention and adverse-event data; these are the evidence gates that could change the thesis.
• Do not infer a read-through to Compass Pathways or atai Life Sciences without compound-specific trial evidence or a material change to their guidance.
• Reassess only if trial funding, regulatory action, or safety data materially changes the development path; worsening cardiovascular safety findings or failure to replicate symptom improvements would falsify the optimistic interpretation.